Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

I'm building a simple FastMCP Server. The application is being compiled with Nuitka. I'm observing a weird behavior where the Server runs into Segmentation Faults when DEBUG Mode is enabled. On ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death. By Gina Kolata A ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Abstract: Multiple recursive generators with constant, as the high-order extension of linear congruence generators, form an important class of pseudorandom number generators that are widely used in ...